



August 9, 2017

The Sherry Lansing Foundation
2121 Avenue of the Stars, Suite 2020
Los Angeles, CA 90067
Phone: 310-788-0057
Via Fax: 310.788.0631

Dear Sherry Lansing,

We are writing to you in your capacity as both a member of the State of California Board of Regents and as someone who has an extensive record of work on cancer research and cancer awareness. Specifically, we are following up on a letter sent by dozens of health groups and academics on May 24, 2017 to the Board of Regents, asking that the University of California withdraw its efforts to obtain a patent on the prostate cancer drug enzalutamide (brand name Xtandi) in India. We are attaching a copy of the May 24th letter, which may or may not have been shared with the Board of Regents, and will briefly summarize that request. The University of California obtained a patent on enzalutamide and that patent is now licensed (worldwide) to Astellas, a Japanese pharmaceutical company. Astellas charges extremely high prices on this drug worldwide. The India patent office has rejected the patent. If the decision in India stands, several generic manufacturers will make enzalutamide available at much lower prices, and in doing so will broaden access, particularly in developing countries. We are in the process of trying to obtain affordable versions of enzalutamide for cancer patients in Chile and in other countries where access is limited. In July, Willy Pino Cataldo, one of the Chilean patients who was working on this effort who needed enzalutamide died

before access could be provided. In the case of Chile as well as in other countries, having access to generic versions manufactured in India is and will be very important.

We would like the Board of Regents to instruct the President to abandon the legal appeal of the rejection of the enzalutamide patent in India. This is an important cancer drug, invented at a public university in California with funding from grants from the US Army and the NIH. The actions by the University will determine if cancer patients in developing countries have access to this medicine. We have yet to receive a response or even acknowledgement of receipt of the May 24th letter from the office of President of the University about this issue, and we think our request merits a response. We are hoping that having spent much of your life working to improve the lives of cancer patients, you will take note of our concerns and bring this to the attention of the President and the Board of Regents.

Sincerely,

Manon Anne Ress, PhD.
Acting Director
Union for Affordable Cancer Treatment
<http://uact.org/> +1.202.332.2670
manon.ress@cancerunion.org

Kirsten Myhr
Board Member
Union for Affordable Cancer Treatment

Antonia Toledo
President
Fundación de Pacientes Un Nuevo Renacer
+56986287667
cancerdemamachile@gmail.com

Germán Inostroza Charnock
President
Corporación Innovarte
+56226886926
contacto@innovarte.cl

Cc: Janet Napolitano, President of the University and ex officio Regent
Paul Monge, Student Regent